Cargando…
Development of Grb2 SH2 Domain Signaling Antagonists: A Potential New Class of Antiproliferative Agents
Aberrant signaling through protein-tyrosine kinase (PTK)-dependent pathways is associated with several proliferative diseases. Accordingly, PTK inhibitors are being developed as new approaches for the treatment of certain cancers. Growth factor receptor bound protein 2 (Grb2) is an important downstr...
Autor principal: | Burke , Terrence R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Kluwer Academic Publishers
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678932/ https://www.ncbi.nlm.nih.gov/pubmed/19444322 http://dx.doi.org/10.1007/s10989-006-9014-7 |
Ejemplares similares
-
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist
por: Zhang, Manchao, et al.
Publicado: (2013) -
Targeting the Interaction between the SH3 Domain of Grb2 and Gab2
por: Malagrinò, Francesca, et al.
Publicado: (2020) -
GRB2 dimerization mediated by SH2 domain-swapping is critical for T cell signaling and cytokine production
por: Sandouk, Aline, et al.
Publicado: (2023) -
Grb2 carboxyl-terminal SH3 domain can bivalently associate with two ligands, in an SH3 dependent manner
por: Arya, Richa, et al.
Publicado: (2017) -
Understanding the mechanism of binding between Gab2 and the C terminal SH3 domain from Grb2
por: Toto, Angelo, et al.
Publicado: (2017)